

*“Innovative devices for treating heart failure”*


**Wilson HTM Healthcare, Biotechnology and Medical Device Investment Conference**

**Victor Windeyer  
Chief Operating Officer**

**October 2006**




# The Bright Lights of Medical Devices




The World at Night

# Target Market: Moderate Heart Failure (NYHA III)



# No Blood Contact



**Benefit with Reduced Risk**




**Freedom to disconnect**

# C-Pulse™ Performs



# US FDA IDE Approval



# Capital Raising Key Features



**Total Raised = \$19.8 million**



**Invests \$8 million**



**Invests \$7 million**



**Invests \$1 million**



**John Brennan to join  
Sunshine Heart Board**



**Issue Price : 0.15**





**3 options for every 10 shares issued, Exercise price 0.20, 3 yr term**

**Two Tranches: (1<sup>st</sup> Tranche 13.8 million ) + (2nd Tranche 6.0 million)**

**Second Tranche subject to FDA approval of IDE application**




# The Capital Raising

	1 <sup>st</sup> Tranche	2 <sup>nd</sup> Tranche	Total
	\$4.8 million	+ \$3.2 million	<b>\$8.0 million</b>
	\$4.2 million	+ \$2.8 million	<b>\$7.0 million</b>
	\$1.0 million		<b>\$1.0 million</b>
INSTITUTIONAL & SOPHISTICATED INVESTORS	\$3.8 million		<b>\$3.8 million</b>
			
<b>Total Raised</b>	<b>\$13.8 million</b>	<b>\$6 million</b>	<b>\$19.8 million</b>






## C-Pulse™ Product & Market Advantage

- **No Blood Contact**
- **Turn on/off**
- **Class III (3x CI IV patients)**
- **Simple Implant @ any CVS center (8x HTx centers)**
- **Cost effective (1/3 total costs of other heart assist devices)**
- **Data compelling**
- **Patented**




# Summary



## Forward looking statements

*This presentation may contain forward looking statements. Various factors could cause actual results to differ materially from these projections including timing, clinical results, financing availability, product sales & marketing or efficacy of products. Although the Company believes that the forward looking statements are reasonable, it can give no assurances that the Company's expectations are correct. All forward looking statements are expressly qualified in their entirety by this cautionary statement.*



*“Innovative devices for treating heart failure”*

**Wilson HTM Healthcare, Biotechnology and Medical Device Investment Conference**

**Victor Windeyer  
Chief Operating Officer**

**October 2006**

